| Trial ID: | L3699 |
| Source ID: | NCT03260881
|
| Associated Drug: |
Liraglutide Pen Injector [Victoza]
|
| Title: |
Liraglutide Effects on Epicardial Fat Inflammatory Genes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes|Coronary Artery Disease
|
| Interventions: |
DRUG: Liraglutide Pen Injector [Victoza]|DRUG: matching liraglutide-placebo pre-filled pens
|
| Outcome Measures: |
Primary: EAT inflammation, EAT inflammation as measured by mRNA and protein expression of Tumor Necrosis Factor (TNF)-Alpha and Interleukin (IL)-6 from blood sample., from a minimum of 4 weeks up to 12 weeks | Secondary: EAT thickness, EAT thickness as measured via ultrasound, from a minimum of 4 weeks up to 12 weeks|SAT inflammation, Subcutaneous Adipose Tissue (SAT) inflammation as measured by mRNA and protein expression of Tumor Necrosis Factor (TNF)-Alpha and Interleukin (IL)-6 from blood sample, from a minimum of 4 weeks up to 12 weeks|EAT GLP-1R, EAT Glucagon-like Peptide-1 Receptor (GLP-1R) mRNA and protein expression from blood sample, from a minimum of 4 weeks up to 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Miami | Collaborators: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
38
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2018-09-01
|
| Completion Date: |
2024-09-05
|
| Results First Posted: |
|
| Last Update Posted: |
2024-09-19
|
| Locations: |
University of Miami, Miami, Florida, 33136, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03260881
|
